These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 28809532)

  • 1. Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer.
    Miao L; Li J; Liu Q; Feng R; Das M; Lin CM; Goodwin TJ; Dorosheva O; Liu R; Huang L
    ACS Nano; 2017 Sep; 11(9):8690-8706. PubMed ID: 28809532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local Blockade of Interleukin 10 and C-X-C Motif Chemokine Ligand 12 with Nano-Delivery Promotes Antitumor Response in Murine Cancers.
    Shen L; Li J; Liu Q; Song W; Zhang X; Tiruthani K; Hu H; Das M; Goodwin TJ; Liu R; Huang L
    ACS Nano; 2018 Oct; 12(10):9830-9841. PubMed ID: 30253648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
    Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
    Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver specific gene immunotherapies resolve immune suppressive ectopic lymphoid structures of liver metastases and prolong survival.
    Goodwin TJ; Shen L; Hu M; Li J; Feng R; Dorosheva O; Liu R; Huang L
    Biomaterials; 2017 Oct; 141():260-271. PubMed ID: 28700955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.
    Feig C; Jones JO; Kraman M; Wells RJ; Deonarine A; Chan DS; Connell CM; Roberts EW; Zhao Q; Caballero OL; Teichmann SA; Janowitz T; Jodrell DI; Tuveson DA; Fearon DT
    Proc Natl Acad Sci U S A; 2013 Dec; 110(50):20212-7. PubMed ID: 24277834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
    Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
    Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance.
    Deng Y; Xia X; Zhao Y; Zhao Z; Martinez C; Yin W; Yao J; Hang Q; Wu W; Zhang J; Yu Y; Xia W; Yao F; Zhao D; Sun Y; Ying H; Hung MC; Ma L
    Nat Commun; 2021 Dec; 12(1):7041. PubMed ID: 34873175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pivotal antitumor role of the immune checkpoint molecule B7-H1 in pancreatic cancer.
    Bazhin AV; von Ahn K; Fritz J; Bunge H; Maier C; Isayev O; Neff F; Siveke JT; Karakhanova S
    Oncoimmunology; 2022; 11(1):2043037. PubMed ID: 35251770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance.
    Fearon DT
    Cancer Immunol Res; 2014 Mar; 2(3):187-93. PubMed ID: 24778314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viro-immune therapy: A new strategy for treatment of pancreatic cancer.
    Ibrahim AM; Wang YH
    World J Gastroenterol; 2016 Jan; 22(2):748-63. PubMed ID: 26811622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring in vivo combinatorial chemo-immunotherapy: Addressing p97 suppression and immune reinvigoration in pancreatic cancer with tumor microenvironment-responsive nanoformulation.
    Lo YL; Li CY; Chou TF; Yang CP; Wu LL; Chen CJ; Chang YH
    Biomed Pharmacother; 2024 Jun; 175():116660. PubMed ID: 38701563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap.
    Song W; Shen L; Wang Y; Liu Q; Goodwin TJ; Li J; Dorosheva O; Liu T; Liu R; Huang L
    Nat Commun; 2018 Jun; 9(1):2237. PubMed ID: 29884866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
    Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
    Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer.
    Zhao J; Wen X; Tian L; Li T; Xu C; Wen X; Melancon MP; Gupta S; Shen B; Peng W; Li C
    Nat Commun; 2019 Feb; 10(1):899. PubMed ID: 30796212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coinhibitory Pathways in Immunotherapy for Cancer.
    Baumeister SH; Freeman GJ; Dranoff G; Sharpe AH
    Annu Rev Immunol; 2016 May; 34():539-73. PubMed ID: 26927206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
    Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
    MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues.
    Hamanishi J; Mandai M; Matsumura N; Abiko K; Baba T; Konishi I
    Int J Clin Oncol; 2016 Jun; 21(3):462-73. PubMed ID: 26899259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies.
    Antonia SJ; Vansteenkiste JF; Moon E
    Am Soc Clin Oncol Educ Book; 2016; 35():e450-8. PubMed ID: 27249753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing Tumor-Infiltrating T Cells through Inhibition of CXCL12 with NOX-A12 Synergizes with PD-1 Blockade.
    Zboralski D; Hoehlig K; Eulberg D; Frömming A; Vater A
    Cancer Immunol Res; 2017 Nov; 5(11):950-956. PubMed ID: 28963140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.
    Liu H; Shen J; Lu K
    Biochem Biophys Res Commun; 2017 Apr; 486(2):239-244. PubMed ID: 28254435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.